NewsBenzingaLas acciones de Novocure caen después de que la FDA rechaza su dispositivo de tratamiento contra el cáncer Las acciones de Novocure caen después de que la FDA rechaza su dispositivo de tratamiento contra el cáncer Benzinga 2026.11.09 16:26 (GMT+0) Open on Benzinga Other news Nvidia’s $105 Billion OpenAI Bet Has a 20-Year Catch Freedom Broker Upgrades Espey Manufacturing to Buy, Maintains Price Target to $70 QUICK SPARK: Chip Stocks Eye Worst Two-Month Drop Since 2008 Carlyle, Clearlake Bet Big On Sports — And PE Deals Are Surging Target's $301 Million Tariff Windfall 'Flattered' Earnings, Analyst Says Freedom Broker Maintains Buy on SKYX Platforms, Lowers Price Target to $2